- Home
- / Summit Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Summit Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$21.8
2024-10-29
Market Capitalization
$16 B
2024-10-29
Revenue
$705 K
FY, 2022
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.4M | 860.0K | 1.8M | 705.0K | |||||
| Gross profit | (12.8M) | 2.7M | (25.3M) | ||||||
| Gross profit margin, % | -50.5% | ||||||||
| General and administrative expense | 12.0M | 12.3M | 9.9M | 19.2M | 23.6M | 26.7M | 30.3M | 60.5M | 556.8M |
| Operating expense total | 41.0M | 51.5M | 41.1M | 72.5M | 109.0M | 78.7M | 90.7M | 211.6M | 1.1B |
| EBIT | (53.2M) | (86.2M) | (72.1M) | (609.6M) | (226.0M) | ||||
| EBIT margin, % | -6185.2% | -4764.3% | -10225.4% | ||||||
| Investment income | 10.4M | 13.5M | |||||||
| Interest income | 4.0K | 1.5M | |||||||
| Interest expense | 255.0K | 281.0K | 4.4M | 16.5M | 8.8M | ||||
| Pre tax profit | (10.9M) | 5.0M | (25.6M) | (52.9M) | (88.6M) | (78.8M) | (614.9M) | (221.3M) | (1.1B) |
| Income tax expense | 3.8M | (2.5M) | (3.5M) | (213.0K) | |||||
| Net Income | (7.1M) | 7.5M | (22.0M) | (52.7M) | (88.6M) | (78.8M) | (614.9M) | (221.3M) | (1.1B) |
| EPS | (0.8) | (1.0) | (0.4) | (1.0) | (0.3) | (1.4) |